Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
Kang-Seo Park, … , Yisong Wang, Giuseppe Giaccone
Kang-Seo Park, … , Yisong Wang, Giuseppe Giaccone
Published June 9, 2014
Citation Information: J Clin Invest. 2014;124(7):3003-3015. https://doi.org/10.1172/JCI73048.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 35

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance

  • Text
  • PDF
Abstract

The majority of non–small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. Unfortunately, a subset of patients with EGFR mutations are refractory to EGFR-TKIs. Resistance to EGFR inhibitors reportedly involves SRC activation and induction of epithelial-to-mesenchymal transition (EMT). Here, we have demonstrated that overexpression of CRIPTO1, an EGF-CFC protein family member, renders EGFR-TKI–sensitive and EGFR-mutated NSCLC cells resistant to erlotinib in culture and in murine xenograft models. Furthermore, tumors from NSCLC patients with EGFR-activating mutations that were intrinsically resistant to EGFR-TKIs expressed higher levels of CRIPTO1 compared with tumors from patients that were sensitive to EGFR-TKIs. Primary NSCLC cells derived from a patient with EGFR-mutated NSCLC that was intrinsically erlotinib resistant were CRIPTO1 positive, but gained erlotinib sensitivity upon loss of CRIPTO1 expression during culture. CRIPTO1 activated SRC and ZEB1 to promote EMT via microRNA-205 (miR-205) downregulation. While miR-205 depletion induced erlotinib resistance, miR-205 overexpression inhibited CRIPTO1-dependent ZEB1 and SRC activation, restoring erlotinib sensitivity. CRIPTO1-induced erlotinib resistance was directly mediated through SRC but not ZEB1; therefore, cotargeting EGFR and SRC synergistically attenuated growth of erlotinib-resistant, CRIPTO1-positive, EGFR-mutated NSCLC cells in vitro and in vivo, suggesting that this combination may overcome intrinsic EGFR-inhibitor resistance in patients with CRIPTO1-positive, EGFR-mutated NSCLC.

Authors

Kang-Seo Park, Mark Raffeld, Yong Wha Moon, Liqiang Xi, Caterina Bianco, Trung Pham, Liam C. Lee, Tetsuya Mitsudomi, Yasushi Yatabe, Isamu Okamoto, Deepa Subramaniam, Tony Mok, Rafael Rosell, Ji Luo, David S. Salomon, Yisong Wang, Giuseppe Giaccone

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2009 Total
Citations: 2 1 4 7 6 6 11 4 7 6 3 1 58
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (58)

Title and authors Publication Year
DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma
Fan W, Xing Y, Yan S, Liu W, Ning J, Tian F, Wang X, Zhan Y, Luo L, Cao M, Huang J, Cai L
Cancer Cell International 2024
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations
Masciale V, Banchelli F, Grisendi G, Samarelli AV, Raineri G, Rossi T, Zanoni M, Cortesi M, Bandini S, Ulivi P, Martinelli G, Stella F, Dominici M, Aramini B
The Journal of Biological Chemistry 2024
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
Laface C, Maselli FM, Santoro AN, Iaia ML, Ambrogio F, Laterza M, Guarini C, De Santis P, Perrone M, Fedele P
Pharmaceutics 2023
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
Calabrese F, Pezzuto F, Lunardi F, Fortarezza F, Tzorakoleftheraki SE, Resi MV, Tiné M, Pasello G, Hofman P
International journal of molecular sciences 2022
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJ, Huang YH, Chang GC
Scientific Reports 2022
CRIPTO Is a Marker of Chemotherapy-Induced Stem Cell Expansion in Non-Small Cell Lung Cancer
Francescangeli F, De Angelis ML, Rossi R, Sette G, Eramo A, Boe A, Guardiola O, Tang T, Yu SC, Minchiotti G, Zeuner A
Frontiers in Oncology 2022
Pyroptosis-Related Gene Model Predicts Prognosis and Immune Microenvironment for Non-Small-Cell Lung Cancer
Luo L, Yao X, Xiang J
Oxidative medicine and cellular longevity 2022
Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy
H Ishii, SM Afify, G Hassan, DS Salomon, M Seno
Cancers 2021
Whence CRIPTO: The Reemergence of an Oncofetal Factor in ‘Wounds’ That Fail to Heal
DW Freeman, ER Sousa, S Karkampouna, E Zoni, PC Gray, DS Salomon, MK Julio, BT Spike
International journal of molecular sciences 2021
EMT‐associated microRNAs and their roles in cancer stemness and drug resistance
G Pan, Y Liu, L Shang, F Zhou, S Yang
2021
Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models
S Gómez-López, ZE Whiteman, SM Janes
2021
Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
R Pathak, VM Villaflor
Cancers 2021
A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
C Kim, SV Liu, J Crawford, T Torres, V Chen, J Thompson, M Tan, G Esposito, DS Subramaniam, G Giaccone
Frontiers in Oncology 2021
Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer
Y Zhang, K Mi, Z Li, L Qiang, M Lv, Y Wu, L Yuan, S Jin
Frontiers in Oncology 2021
A Multidisciplinary Review of the Roles of Cripto in the Scientific Literature Through a Bibliometric Analysis of its Biological Roles
ER Sousa, E Zoni, S Karkampouna, FL Manna, PC Gray, MD Menna, MK Julio
Cancers 2020
Conditional reprogramming: next generation cell culture
X Wu, S Wang, M Li, J Li, J Shen, Y Zhao, J Pang, Q Wen, M Chen, B Wei, PJ Kaboli, F Du, Q Zhao, CH Cho, Y Wang, Z Xiao, X Wu
Acta pharmaceutica Sinica. B 2020
Structure and Characterization of a Covalent Inhibitor of Src Kinase
D Gurbani, G Du, NJ Henning, S Rao, AK Bera, T Zhang, NS Gray, KD Westover
Frontiers in Molecular Biosciences 2020
Characterizing heterogeneity of non‐small cell lung tumour microenvironment to identify signature prognostic genes
K Mi, F Chen, Z Qian, J Chen, D Lv, C Zhang, Y Xu, H Wang, Y Zhang, Y Jiang, D Shang
Journal of Cellular and Molecular Medicine 2020
Conditional cell reprogramming for modeling host‐virus interactions and human viral diseases
X Liu, AM Mondal
Journal of Medical Virology 2020
Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line
Z He, F Gong, J Liao, Q Wang, Y Su, C Chen, J Lin, R Lin
Translational cancer research 2020
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
BC Creelan, JE Gray, T Tanvetyanon, AA Chiappori, T Yoshida, MJ Schell, SJ Antonia, EB Haura
British Journal of Cancer 2019
MicroRNA in Lung Cancer Metastasis
SG Wu, TH Chang, YN Liu, JY Shih
Cancers 2019
Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs
M Farhan, A Malik, M Ullah, S Afaq, M Faisal, A Farooqi, B Biersack, R Schobert, A Ahmad
International journal of molecular sciences 2019
Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
SR, Melchior, Urbanska, Jakobsen, Stricker, Grauslund, Sørensen
Cancers 2019
Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
PC, Krawczyk, Dakic, Simic, Yuan, Blancato, Wang, Hubbard, Zheng, Dan, Strome, Cullen, Davidson, Deeken, Choudhury, Ahn, Agarwal, Zhou, Schlegel, Furth, Pan, Liu
Cells 2019
Circular RNA circ‐CMPK1 contributes to cell proliferation of non‐small cell lung cancer by elevating cyclin D1 via sponging miR‐302e
D Cui, R Qian, Y Li
Molecular Genetics & Genomic Medicine 2019
Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
S Rayego-Mateos, R Rodrigues-Diez, JL Morgado-Pascual, F Valentijn, JM Valdivielso, R Goldschmeding, M Ruiz-Ortega
Mediators of Inflammation 2018
Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
Y Pan, L Jiao, C Lin, C Lu, L Li, H Chen, Y Wang, Y He
Biologics : targets & therapy 2018
Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors: 3T3+Y for NSCLC cell culture
RE Hynds, AB Aissa, KH Gowers, TB Watkins, L Bosshard-Carter, AJ Rowan, S Veeriah, GA Wilson, SA Quezada, C Swanton, SM Janes
International Journal of Cancer 2018
Role of miR‑23a/Zeb1 negative feedback loop in regulating epithelial‑mesenchymal transition and tumorigenicity of intraocular tumors
Y Wang, Y Luo, W Guan, H Zhao
Oncology Letters 2018
High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer
KS Park, YW Moon, M Raffeld, DH Lee, Y Wang, G Giaccone
Lung cancer (Amsterdam, Netherlands) 2018
Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells by mTOR activation through Akt-independent pathway
S Yamazaki, Y Higuchi, M Ishibashi, H Hashimoto, M Yasunaga, Y Matsumura, K Tsuchihara, M Tsuboi, K Goto, A Ochiai, G Ishii
Cancer Science 2018
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
GM OKane, TA Barnes, NB Leighl
Current Oncology 2018
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
T Jiang, C Su, S Ren, F Cappuzzo, G Rocco, JD Palmer, N van Zandwijk, F Blackhall, X Le, NA Pennell, C Zhou
Journal of Thoracic Disease 2018
Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors
CL Sambrooks, M Baro, A Quijano, A Narayan, W Cui, P Greninger, R Egan, A Patel, CH Benes, WM Saltzman, JN Contessa
Cancer research 2018
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
PC Lee, YF Fang, H Yamaguchi, WJ Wang, TC Chen, X Hong, B Ke, W Xia, Y Wei, Z Zha, Y Wang, HP Kuo, CW Wang, CY Tu, CH Chen, WC Huang, SF Chiang, L Nie, J Hou, CT Chen, L Huo, WH Yang, R Deng, K Nakai, YH Hsu, SS Chang, TJ Chiu, J Tang, R Zhang, L Wang, B Fang, T Chen, KK Wong, JL Hsu, MC Hung
Cancer Cell 2018
[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer]
Li Yu, Sha Huang, Wang Lv, Zhehao He, Jian Hu
Zhongguo fei ai za zhi = Chinese journal of lung cancer 2018
Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer
A Legras, N Pécuchet, S Imbeaud, K Pallier, A Didelot, H Roussel, L Gibault, E Fabre, FL Pimpec-Barthes, P Laurent-Puig, H Blons
Cancers 2017
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
B Ricciuti, S Baglivo, L Paglialunga, AD Giglio, G Bellezza, R Chiari, L Crinò, G Metro
Therapeutic advances in medical oncology 2017
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
E Ichihara, D Westover, CB Meador, Y Yan, JA Bauer, P Lu, F Ye, A Kulick, E Stanchina, R McEwen, M Ladanyi, D Cross, W Pao, CM Lovly
Cancer research 2017
Clinical significance of cripto-1 expression in lung adenocarcinoma
H Zhang, B Zhang, L Gao, L Zhang, K Zhu, R Cheng, C Wang
Oncotarget 2017
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
J Wang, B Wang, H Chu, Y Yao
OncoTargets and therapy 2016
miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway
J Han, F Zhao, J Zhang, H Zhu, H Ma, X Li, L Peng, J Sun, Z Chen
International journal of oncology 2016
Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
AN Phan, TN Hua, MK Kim, VT Vo, JW Choi, HW Kim, JK Rho, KW Kim, Y Jeong
Oncotarget 2016
Resisting Resistance: Targeted Therapies in Lung Cancer
JJ Lin, AT Shaw
Trends in Cancer 2016
Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non–Small-Cell Lung Cancer
VR Bhatt, SP DSouza, LM Smith, AM Cushman-Vokoun, V Noronha, V Verma, A Joshi, A Chougule, N Jambhekar, A Kessinger, A Marr, V Patil, SD Banavali, AK Ganti, K Prabhash
Journal of Global Oncology 2016
Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions
B Gao, C Huang, K Kernstine, V Pelekanou, Y Kluger, T Jiang, JR Peters-Hall, M Coquelin, L Girard, W Zhang, K Huffman, D Oliver, F Kinose, E Haura, JK Teer, U Rix, AT Le, DL Aisner, MV Garcia, RC Doebele, KR Covington, OA Hampton, HV Doddapaneni, JC Jayaseelan, J Hu, DA Wheeler, JW Shay, DL Rimm, A Gazdar, JD Minna
Oncotarget 2016
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
F Morgillo, CM Corte, M Fasano, F Ciardiello
ESMO Open 2016
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
L Huang, L Fu
Acta Pharmaceutica Sinica B 2015
Refining the treatment of NSCLC according to histological and molecular subtypes
A Thomas, SV Liu, DS Subramaniam, G Giaccone
Nature Reviews Clinical Oncology 2015
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
R Pagliarini, W Shao, WR Sellers
EMBO reports 2015
Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer
Y Chen, L Lu, B Feng, S Han, S Cui, X Chu, L Chen, R Wang
Oncotarget 2015
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra A, Mishra L, Li S
Oncotarget 2015
CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities
Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F
Oncotarget 2015
Genetic modifiers of EGFR dependence in non-small cell lung cancer
T Sharifnia, V Rusu, F Piccioni, M Bagul, M Imielinski, AD Cherniack, CS Pedamallu, B Wong, FH Wilson, LA Garraway, D Altshuler, TR Golub, DE Root, A Subramanian, M Meyerson
Proceedings of the National Academy of Sciences 2014
MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use
SP Nana-Sinkam, CM Croce
Genome biology 2014
Cripto-1 as a novel therapeutic target for triple negative breast cancer
Castro NP, Fedorova-Abrams ND, Merchant AS, Rangel MC, Nagaoka T, Karasawa H, Klauzinska M, Hewitt SM, Biswas K, Sharan SK, Salomon DS
Oncotarget 2014
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 4 news outlets
Posted by 4 X users
Referenced in 7 patents
70 readers on Mendeley
See more details